ES2066062T3 - Preparacion de liberacion sostenida para administracion al cerebro. - Google Patents

Preparacion de liberacion sostenida para administracion al cerebro.

Info

Publication number
ES2066062T3
ES2066062T3 ES90115389T ES90115389T ES2066062T3 ES 2066062 T3 ES2066062 T3 ES 2066062T3 ES 90115389 T ES90115389 T ES 90115389T ES 90115389 T ES90115389 T ES 90115389T ES 2066062 T3 ES2066062 T3 ES 2066062T3
Authority
ES
Spain
Prior art keywords
brain
administration
preparation
sustained release
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90115389T
Other languages
English (en)
Inventor
Toru Hayakawa
Toshiki Yoshimine
Keiji Fujioka
Yoshihiro Takada
Yoshio Sasaki
Tsunemasa Irie
Nobuyuki Fukushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Pharmaceuticals Co Ltd filed Critical Koken Co Ltd
Application granted granted Critical
Publication of ES2066062T3 publication Critical patent/ES2066062T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE EL USO DE UNA SUSTANCIA FARMACEUTICAMENTE ACTIVA PARA EL TRATAMIENTO DE ENFERMEDADES CEREBRALES MEDIANTE LA ADMINISTRACION AL CEREBRO DE DICHA SUSTANCIA EN FORMA DE UNA PREPARACION QUE COMPRENDE A DICHA SUSTANCIA INCORPORADA EN UN PORTADOR BIODEGRADABLE.
ES90115389T 1989-08-10 1990-08-10 Preparacion de liberacion sostenida para administracion al cerebro. Expired - Lifetime ES2066062T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20848489 1989-08-10

Publications (1)

Publication Number Publication Date
ES2066062T3 true ES2066062T3 (es) 1995-03-01

Family

ID=16556927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90115389T Expired - Lifetime ES2066062T3 (es) 1989-08-10 1990-08-10 Preparacion de liberacion sostenida para administracion al cerebro.

Country Status (6)

Country Link
EP (1) EP0412554B1 (es)
JP (1) JP3187410B2 (es)
AT (1) ATE113470T1 (es)
DE (1) DE69013797T2 (es)
DK (1) DK0412554T3 (es)
ES (1) ES2066062T3 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI924134L (fi) 1990-03-20 1992-09-16 Amrad Corp Ltd Foerfarande foer reglering av utvecklingen och bevarandet av en neuron
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
BR9205864A (pt) * 1991-04-08 1994-06-28 Sumitomo Pharma Formulações sólidas porosas contendo substâncias proteináceas fisiologicamente ativas.
CA2109955A1 (en) * 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
WO1994006455A1 (en) * 1992-09-14 1994-03-31 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
IL122802A0 (en) * 1995-07-03 1998-08-16 Koken Kk Gene preparations
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
WO1997044057A1 (en) * 1996-05-21 1997-11-27 Cytotherapeutics, Inc. System and method for delivery of cytokines using encapsulated cytokine-secreting cells
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
EP1407787B1 (en) 2001-06-20 2009-04-29 Dainippon Sumitomo Pharma Co., Ltd. Method of promoting nucleic acid transfer
CN108840924A (zh) * 2018-06-20 2018-11-20 罗国球 一种高蛋白含量脑蛋白水解物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139286B1 (en) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Prolonged sustained-release preparations
DE3688188T2 (de) * 1985-12-27 1993-10-14 Koken Kk Verfahren zur Herstellung einer Formulierung mit verzögerter Freisetzung.
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
DK0412554T3 (da) 1994-12-12
EP0412554B1 (en) 1994-11-02
JP3187410B2 (ja) 2001-07-11
DE69013797T2 (de) 1995-05-18
EP0412554A2 (en) 1991-02-13
JPH03163032A (ja) 1991-07-15
EP0412554A3 (en) 1991-09-25
DE69013797D1 (de) 1994-12-08
ATE113470T1 (de) 1994-11-15

Similar Documents

Publication Publication Date Title
ES2066062T3 (es) Preparacion de liberacion sostenida para administracion al cerebro.
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES2074124T5 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
ES2128369T3 (es) Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2056832T3 (es) Un vehiculo de liberacion para un ingrediente activo.
PT850046E (pt) Microemulsoes para utilizacao como veiculos para administracao de compostos activos
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
MX9307686A (es) Preparacion de liberacion sostenida.
ES491621A0 (es) Procedimiento para producir un preparado farmaceutico en forma de una pelicula de poliacrilato, adecuado para aplicacionpor via transdermal.
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
ES2069582T3 (es) Nucleosidos terapeuticos.
CO5190688A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma de compuesto formado in situ con una hidrosolubilidad 100 mg/ml, y procedimientos para su preparac
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
ES2181742T3 (es) Derivados de benzoimidazol, su produccion y uso como antagonistas de angiotensina ii.
MX9201730A (es) Nuevos fenilazacicloalcanos substituidos que actuan centralmente.
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ES2092296T3 (es) Metodo de tratamiento de tejidos infectados.
ES2195220T3 (es) Acidos sulfonilaminocarboxilicos.
ES2165640T3 (es) Acidos diaminocarboxilicos sustituidos.
ES2085337T3 (es) Comprimidos farmaceuticos.
AR032293A1 (es) Estuche farmaceutico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 412554

Country of ref document: ES